| Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ... Journal of clinical oncology 31 (5), 616, 2013 | 886 | 2013 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 305 | 2022 |
| Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients … SJ O'Day, AMM Eggermont, V Chiarion-Sileni, R Kefford, JJ Grob, ... Journal of Clinical Oncology 31 (9), 1211-1218, 2013 | 221 | 2013 |
| Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 D Hannani, M Vétizou, D Enot, S Rusakiewicz, N Chaput, D Klatzmann, ... Cell research 25 (2), 208-224, 2015 | 183 | 2015 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 171 | 2022 |
| Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study H Gogas, B Dréno, J Larkin, L Demidov, D Stroyakovskiy, Z Eroglu, ... Annals of Oncology 32 (3), 384-394, 2021 | 83 | 2021 |
| BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients J Mackiewicz, A Mackiewicz Contemporary Oncology/Współczesna Onkologia 2018 (1), 68-72, 2018 | 82 | 2018 |
| lncRNA in HNSCC: challenges and potential K Guglas, M Bogaczyńska, T Kolenda, M Ryś, A Teresiak, R Bliźniak, ... Contemporary Oncology/Współczesna Onkologia 21 (4), 259-266, 2017 | 79 | 2017 |
| Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind … GV Long, JJ Luke, MA Khattak, L de la Cruz Merino, M Del Vecchio, ... The Lancet Oncology 23 (11), 1378-1388, 2022 | 76 | 2022 |
| Therapeutic gene modified cell based cancer vaccines A Kozłowska, J Mackiewicz, A Mackiewicz Gene 525 (2), 200-207, 2013 | 65 | 2013 |
| Oncogenic role of ZFAS1 lncRNA in head and neck squamous cell carcinomas T Kolenda, K Guglas, M Kopczyńska, A Teresiak, R Bliźniak, ... Cells 8 (4), 366, 2019 | 53 | 2019 |
| Biological role of long non-coding RNA in head and neck cancers T Kolenda, K Guglas, M Ryś, M Bogaczyńska, A Teresiak, R Bliźniak, ... Reports of practical Oncology and Radiotherapy 22 (5), 378-388, 2017 | 47 | 2017 |
| Sodium butyrate and short chain fatty acids in prevention of travellers' diarrhoea: a randomized prospective study L Krokowicz, BF Kaczmarek, P Krokowicz, Z Stojcev, J Mackiewicz, ... Travel Medicine and Infectious Disease 12 (2), 183-188, 2014 | 37 | 2014 |
| Design of clinical trials for therapeutic cancer vaccines development J Mackiewicz, A Mackiewicz European journal of pharmacology 625 (1-3), 84-89, 2009 | 36 | 2009 |
| LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, VC Sileni, ... Annals of Oncology 32, S1314-S1315, 2021 | 34 | 2021 |
| Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection A Mackiewicz, J Mackiewicz, PJ Wysocki, M Wiznerowicz, M Kapcinska, ... Expert opinion on investigational drugs 21 (6), 773-783, 2012 | 32 | 2012 |
| Integrins as a new target for cancer treatment I Łasińska, J Mackiewicz Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2019 | 31 | 2019 |
| years of negative pressure wound therapy [NPWT]: evolution of indications for its use L Krokowicz, M Borejsza-Wysocki, J Mackiewicz, A Iqbal, M Drews Negative Pressure Wound Therapy 1 (1), 27-32, 2014 | 31 | 2014 |
| PRINS lncRNA is a new biomarker candidate for HPV infection and prognosis of head and neck squamous cell carcinomas M Kopczyńska, T Kolenda, K Guglas, J Sobocińska, A Teresiak, ... Diagnostics 10 (10), 762, 2020 | 27 | 2020 |
| Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma … AM Arance, H Gogas, B Dreno, KT Flaherty, L Demidov, D Stroyakovskiy, ... Annals of Oncology 30, v906, 2019 | 27 | 2019 |
